(b) Results from multivariate analyses
| DMF | . | . | . | . |
0.62
(0.40, 0.95) |
. |
0.34
(0.12, 0.98) |
. |
|---|---|---|---|---|---|---|---|---|
| 1.14 (0.58, 2.22) |
FNG | . | . | . |
0.55
(0.32, 0.94) |
. | . | . |
| 0.95 (0.46, 1.96) |
0.84 (0.38, 1.87) |
GA | . | . | 0.65 (0.36, 1.19) |
. | . | . |
| 1.49 (0.70, 3.14) |
1.31 (0.57, 3.01) |
1.56 (0.65, 3.74) |
IFN | . |
0.36
(0.18, 0.72) |
. | 0.49 (0.10, 2.46) |
. |
| 1.24 (0.67, 2.30) |
1.09 (0.53, 2.24) |
1.30 (0.61, 2.80) |
0.83 (0.38, 1.84) |
NTZ |
0.51
(0.31, 0.86) |
. |
0.23
(0.07, 0.78) |
. |
|
0.62
(0.42, 0.93) |
0.55
(0.32, 0.94) |
0.65 (0.36, 1.19) |
0.42
(0.22, 0.79) |
0.50
(0.31, 0.81) |
No DMT | 0.61 (0.37, 1.02) |
0.39
(0.20, 0.75) |
1.37 (0.80, 2.36) |
|
0.38
(0.20, 0.73) |
0.34
(0.16, 0.70) |
0.40
(0.18, 0.88) |
0.26
(0.11, 0.58) |
0.31
(0.15, 0.62) |
0.61 (0.37, 1.02) |
OCR | . | . |
|
0.32
(0.18, 0.57) |
0.28
(0.14, 0.58) |
0.34
(0.16, 0.73) |
0.22
(0.10, 0.46) |
0.26
(0.14, 0.48) |
0.52
(0.32, 0.83) |
0.84 (0.42, 1.69) |
RTX | 0.93 (0.19, 4.57) |
| 0.77 (0.40, 1.47) |
0.67 (0.32, 1.42) |
0.80 (0.37, 1.77) |
0.52 (0.23, 1.17) |
0.62 (0.31, 1.24) |
1.23 (0.74, 2.06) |
2.01 (0.97, 4.15) |
2.39
(1.22, 4.66) |
TRF |
On the upper triangle, the effect size are direct comparisons; the effect sizes presented on lower triangle are network meta-analyses (indirect comparison). Comparisons should be read from left to right (example for upper triangle: OR (95% CI) of developing a severe COVID-19 in DMF compared to no DMT is 0.62 (0.40, 0.95); example for lower triangle: OR (95% CI) of developing a severe COVID-19 in DMF compared to FNG is 1.14 (0.58, 2.22). DMF: dimethyl fumarate; FNG: fingolimod; GA: glatiramer acetate; IFN: interferon; NTZ: natalizumab; TRF: teriflunomide; DMT: disease-modifying therapy; RTX: rituximab; OCR: ocrelizumab.